Adjuvant capecitabine in residual triple-negative breast cancer after carboplatin-based neoadjuvant chemotherapy: a real-world cohort
Introduction: Patients with triple-negative breast cancer (TNBC) who do not achieve pathologic complete response (pCR) after neoadjuvant chemotherapy have a worse prognosis. Adjuvant capecitabine has demonstrated benefit in selected populations, but its role after prior carboplatin exposure remains uncertain, particula...